MRNAModerna, Inc.

Filed with the SEC on September 30, 2026 | Current Price: $191.50 | Today's Change: -5.88%

---

What Happened

Moderna filed an 8-K with the SEC on September 30, 2026, disclosing a leadership change (Item 5.02), a Regulation FD disclosure (Item 7.01), and accompanying financial exhibits (Item 9.01). The filing includes structured financial data for Q2 FY2026 showing revenue from contracts with customers of $250 million, a net loss of $1.796 billion, and a basic and diluted loss per share of $4.64. Operating losses reached $1.957 billion in the quarter, underscoring the severity of the company's ongoing financial pressure.

---

Why It Matters

The Q2 FY2026 figures embedded in this filing reveal a company burning through cash at a substantial pace while generating minimal top-line revenue. The $250 million in contract revenue represents a dramatic decline from the $10.815 billion in revenues reported in Q2 FY2023 — a period that reflected peak COVID-19 vaccine demand. The operating loss of nearly $2 billion in a single quarter, against just $250 million in revenue, signals that Moderna's cost structure remains heavily weighted toward R&D and infrastructure spending that its current commercial revenues cannot support. The simultaneous disclosure of an executive departure (Item 5.02) adds another layer of uncertainty at a time when the company faces acute revenue challenges.

Key figures at a glance:

• Q2 FY2026 Revenue (contract): $250 million
• Q2 FY2026 Net Loss: -$1.796 billion
• Q2 FY2026 Operating Loss: -$1.957 billion
• Q2 FY2026 EPS (basic & diluted): -$4.64

---

Analysis

This filing paints a starkly different picture from Moderna's pandemic-era financial performance. The revenue base has contracted by roughly 97% from its Q2 FY2023 peak, and the company's losses in Q2 FY2026 alone dwarf the quarter's entire revenue intake by nearly an 8-to-1 ratio on an operating basis. This is not a story of gradual normalization — it reflects a structural mismatch between Moderna's current commercial stage and the scale of its operations.

The executive change disclosed under Item 5.02 warrants attention in this context. Leadership transitions during periods of financial stress can signal strategic pivots, restructuring efforts, or internal disagreements about direction — though the filing alone does not specify the nature or circumstances of the departure.

For investors, the key question going forward is whether Moderna's pipeline — particularly its non-COVID-19 mRNA programs in respiratory viruses, oncology, and rare diseases — can begin generating meaningful revenue before the company's cash reserves are exhausted. The Q2 FY2026 operating loss rate, if sustained, would represent an extraordinarily high burn. Investors should watch closely for any forward guidance, pipeline milestone announcements, or restructuring actions that accompany or follow this filing.

This filing follows StockWatch's existing Initiating Coverage on Moderna — readers are encouraged to consult that report for deeper fundamental context.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Moderna's SEC filing dated September 30, 2026, and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell any security, or a recommendation of any kind. No rating or price target is issued in this report. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

Existing Coverage

StockWatch has full coverage on MRNA, published 2026-09-11. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-09-30. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337d8k.htm